Key result
Cardiac tropomyosin does not undergo significant structural changes during the development of dilated cardiomyopathy, and only a small percentage of patients exhibit low-immunoreactivity autoantibodies against it.
Case-Control (n=66)
Answers are grounded in this paper and cite their sources.
Does not support tropomyosin autoantibody testing in DCM; hypothesis-generating for other pathogenic mechanisms.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Сидорик et al. (1998) conducted a case-control in Dilated cardiomyopathy (n=66). Dilated cardiomyopathy vs. Healthy donors was evaluated on Presence of autoantibodies to cardiac tropomyosin. Cardiac tropomyosin does not undergo significant structural changes during the development of dilated cardiomyopathy, and only a small percentage of patients exhibit low-immunoreactivity autoantibodies against it.
Synapse has enriched 10 related papers. Consider them for comparative context: